Smad1/5/8 are myogenic regulators of murine and human mesoangioblasts

Area of Science:

• Stem cell biology
• Muscle regeneration
• Molecular signaling

Background:

• Mesoangioblasts (MABs) are vessel-associated stem cells crucial for skeletal muscle regeneration.
• The molecular mechanisms governing MAB myogenic commitment are not fully understood.
• Bone morphogenetic protein (BMP) signaling is known to influence adult myogenic precursor cells.

Purpose of the Study:

• To investigate the role of BMP signaling in regulating the myogenic potential of embryonic and adult MABs.
• To explore the therapeutic implications of modulating BMP signaling for MAB-based muscle repair.

Main Methods:

• In vitro and in vivo studies using embryonic and adult MABs.
• Manipulation of BMP signaling pathways using Dorsomorphin (DM) and siRNA-mediated knockdown of Smad8.
• Assessment of MAB myogenic differentiation and functional recovery in mouse models of muscular dystrophy (Sgca-null) and acute muscle damage.

Main Results:

• BMP signaling addition inhibited MAB myogenic differentiation.
• Interference with BMP-BMP receptor interactions, Smad8 knockdown, or Smad8 deletion enhanced MAB myogenic differentiation.
• DM-treated MABs showed improved efficacy in restoring α-sarcoglycan (αSG) protein levels and muscle function in Sgca-null mice.
• DM-treated MABs exhibited enhanced myogenic potential in acute muscle damage models.
• SMADs were found to control the myogenic commitment of human MABs (hMABs).

Conclusions:

• BMP signaling negatively regulates MAB myogenic differentiation and potential.
• Inhibiting BMP signaling, particularly via SMADs, enhances MAB myogenic capacity.
• BMP signaling antagonists represent promising therapeutic candidates to improve MAB-based regenerative medicine strategies for muscle diseases.